Ubs Group Ag Collegium Pharmaceutical, Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Ubs Group Ag holds 36,221 shares of COLL stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,221

Previous 23,273 55.64%

Holding current value

$1.04 Million

Previous $749,000 86.78%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$31.4 - $39.07 $406,567 - $505,878	12,948 Added 55.64%	36,221 $1.4 Million
Q2 2024 Aug 13, 2024	SELL	$31.36 - $39.99 $261,166 - $333,036	-8,328 Reduced 26.35%	23,273 $749,000
Q1 2024 May 13, 2024	BUY	$31.23 - $40.91 $887,806 - $1.16 Million	28,428 Added 895.93%	31,601 $1.23 Million
Q4 2023 Feb 09, 2024	BUY	$21.16 - $30.8 $10,051 - $14,630	475 Added 17.61%	3,173 $97,000
Q3 2023 Nov 09, 2023	SELL	$21.23 - $24.28 $186,781 - $213,615	-8,798 Reduced 76.53%	2,698 $60,000
Q2 2023 Aug 11, 2023	BUY	$21.06 - $24.0 $35,486 - $40,440	1,685 Added 17.17%	11,496 $247,000
Q1 2023 May 12, 2023	BUY	$23.0 - $29.88 $179,768 - $233,542	7,816 Added 391.78%	9,811 $235,000
Q4 2022 Feb 08, 2023	SELL	$16.14 - $23.55 $25,194 - $36,761	-1,561 Reduced 43.9%	1,995 $46,000
Q3 2022 Nov 10, 2022	BUY	$15.46 - $20.1 $41,231 - $53,606	2,667 Added 300.0%	3,556 $57,000
Q2 2022 Aug 10, 2022	SELL	$14.22 - $20.88 $13,509 - $19,836	-950 Reduced 51.66%	889 $16,000
Q1 2022 May 16, 2022	SELL	$17.2 - $22.5 $21,723 - $28,417	-1,263 Reduced 40.72%	1,839 $37,000
Q4 2021 Feb 14, 2022	SELL	$17.5 - $21.35 $16,502 - $20,133	-943 Reduced 23.31%	3,102 $58,000
Q3 2021 Nov 15, 2021	SELL	$17.75 - $25.39 $210,266 - $300,769	-11,846 Reduced 74.55%	4,045 $79,000
Q2 2021 Aug 13, 2021	SELL	$21.74 - $25.28 $74,372 - $86,482	-3,421 Reduced 17.71%	15,891 $376,000
Q1 2021 May 12, 2021	BUY	$19.25 - $26.1 $76,249 - $103,382	3,961 Added 25.8%	19,312 $458,000
Q4 2020 Feb 11, 2021	BUY	$17.83 - $22.29 $187,018 - $233,799	10,489 Added 215.73%	15,351 $308,000
Q3 2020 Nov 12, 2020	SELL	$15.78 - $20.82 $224,423 - $296,102	-14,222 Reduced 74.52%	4,862 $102,000
Q2 2020 Jul 31, 2020	SELL	$15.49 - $23.51 $56,615 - $85,929	-3,655 Reduced 16.07%	19,084 $334,000
Q1 2020 May 01, 2020	SELL	$13.89 - $25.45 $382,280 - $700,434	-27,522 Reduced 54.76%	22,739 $372,000
Q4 2019 Feb 14, 2020	BUY	$10.7 - $22.24 $222,677 - $462,836	20,811 Added 70.67%	50,261 $1.03 Million
Q3 2019 Nov 14, 2019	BUY	$10.16 - $13.28 $271,068 - $354,310	26,680 Added 963.18%	29,450 $338,000
Q2 2019 Aug 14, 2019	SELL	$10.62 - $16.59 $19,647 - $30,691	-1,850 Reduced 40.04%	2,770 $36,000
Q1 2019 May 14, 2019	SELL	$13.58 - $18.72 $49,146 - $67,747	-3,619 Reduced 43.93%	4,620 $70,000
Q4 2018 Feb 14, 2019	SELL	$14.78 - $19.68 $3,177 - $4,231	-215 Reduced 2.54%	8,239 $141,000
Q3 2018 Nov 14, 2018	SELL	$14.16 - $24.3 $857,586 - $1.47 Million	-60,564 Reduced 87.75%	8,454 $124,000
Q2 2018 Aug 14, 2018	SELL	$21.79 - $28.29 $2.9 Million - $3.76 Million	-132,940 Reduced 65.83%	69,018 $1.65 Million
Q1 2018 May 15, 2018	BUY	$18.15 - $29.21 $929,352 - $1.5 Million	51,204 Added 33.97%	201,958 $5.16 Million
Q4 2017 Feb 14, 2018	BUY	$9.3 - $19.14 $1.3 Million - $2.68 Million	139,824 Added 1279.27%	150,754 $2.78 Million
Q3 2017 Nov 14, 2017	SELL	$9.15 - $11.97 $94,922 - $124,176	-10,374 Reduced 48.7%	10,930 $114,000
Q2 2017 Aug 14, 2017	BUY	N/A	7,537 Added 54.75%	21,304 $267,000
Q1 2017 Nov 14, 2017	BUY	N/A	13,767	13,767 $139,000

Others Institutions Holding COLL

# of Institutions

254

Shares Held

36.9M

Call Options Held

100K

Put Options Held

21.1K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $977M
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account